Status:
TERMINATED
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetic Retinopathy
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802. During this extension study, all patients will receive open...
Eligibility Criteria
Inclusion
- written informed consent provided prior to participation in the extension study
- successful completion of study CSMS995 0802
- willingness to comply with all study requirements
Exclusion
- more than 8 weeks interval since the completion of study CSMS995 0802
- premature discontinuation from study CSMS995 0802
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00248131
Start Date
November 1 2005
End Date
July 1 2006
Last Update
April 10 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.